Saturday 17 October 2026 Export DRTS’s income statement to Excel — free account

Alpha Tau Medical Ltd.

In the quarter to June 2026, EPS fell 100.0%, free cash flow fell 30.4% and total debt rose 12.8%, each against the same quarter a year earlier.

12.29 0.87 −6.61%

Follow DRTS

Alert me

Market cap: $1.2B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.56

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	4	3	2	—	—

Insider Ownership 17.82%

Capital & Financial Ratios $m

Market Cap 1,220.00

Revenue —

Net Income (87.56)

Free Cash Flow (39.09)

Net Debt (93.83)

Current Ratio 11.09

Debt/Equity 0.15

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 25.03

Past 5Y EPS Growth —

This Y EPS Growth (80.57%)

Next Y EPS Growth 44.10%

Next Y revenue growth —

Next 5Y EPS Growth 10.86%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 88.40%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	82	60	73	101
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	3	3	4	4
	86	64	78	107

	2023	2024	2025	Q'26
Payables	3	4	4	3
ST’ Debt	—	—	—	—
Other	—	—	—	—
	7	9	11	10

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(9.97%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	(1)	—	—	—
’25	—	(15)	—	—	(27)
’24	—	(13)	—	—	(20)
’23	—	—	—	—	(18)
’22	(7)	—	—	—	(24)
’21	(3)	3	0	(11)	(12)
’20	—	—	0	0	(7)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	(1)	—	—	—
’25	—	(18)	—	—	(33)
’24	—	(13)	—	—	(22)
’23	—	(1)	—	—	(24)
’22	(7)	—	—	(1)	(25)
’22	—	—	—	—	(24)
’21	(4)	3	0	(14)	(15)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.26)	—	—	—	—
’25	(0.12)	—	—	—	(0.53)
’24	(0.11)	—	—	—	(0.45)
’23	(0.12)	(0.13)	(0.07)	—	(0.42)
’22	(0.54)	(0.03)	(0.04)	(0.04)	(0.53)
’21	(0.29)	(0.17)	(0.12)	(0.09)	(0.67)
’20	—	—	0.00	0.00	(0.22)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	9.58	3.00	2.70	1.75	2.30	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	10.10	20.65	5.95	3.40	5.21
People
People	Employees	—	—	—	—	2	83	94	121	112	121
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	0.00	0.00	0.00	—	—	—
	EBT	—	—	—	(8)	(9)	(27)	(34)	(29)	(32)	(43)
	EBT margin, %	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	—	(8)	(9)	(27)	(34)	(29)	(32)	(43)
	Depreciation	—	—	—	0	0	1	1	1	1	1
Per share, $
Per share, $	Revenue	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	(0.25)	(0.22)	(0.67)	(0.53)	(0.42)	(0.45)	(0.53)
	Cash flow	—	—	—	(0.20)	(0.18)	(0.29)	(0.38)	(0.26)	(0.28)	(0.33)
	Capex	—	—	—	(0.04)	(0.09)	(0.07)	(0.01)	(0.09)	(0.03)	(0.08)
	Free cash flow	—	—	—	(0.24)	(0.27)	(0.36)	(0.39)	(0.35)	(0.31)	(0.41)
	Book value	—	—	—	0.00	(0.21)	(0.86)	1.66	1.22	0.90	0.96
	Shares, m	—	—	—	34	40	41	64	69	70	81
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(7)	(7)	(12)	(24)	(18)	(20)	(27)
	Capex	—	—	—	(1)	(4)	(3)	(1)	(6)	(2)	(6)
	Free cash flow	—	—	—	(8)	(11)	(15)	(25)	(24)	(22)	(33)
Balance, $m
Balance, $m	Working capital	—	—	—	—	45	28	102	79	56	68
	Total debt	—	—	—	—	54	54	5	6	6	6
	Net debt	—	—	—	—	(47)	(32)	(105)	(76)	(54)	(67)
	Shareholders’ equity	—	—	—	—	(8)	(35)	106	84	63	77
Returns, %
Returns, %	ROA	—	—	—	0.00	(16.76)	(57.29)	(41.59)	(25.63)	(32.80)	(44.44)
	ROIC	—	—	—	0.00	0.00	0.00	(7,250.90)	(268.77)	(261.11)	(255.98)
	ROE	—	—	—	0.00	105.37	126.24	(95.27)	(30.67)	(43.16)	(61.00)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
GHRS GH Research PLC	$1.3B	— (loss-making)	—	—	n/m	−66.62% (below 0%: shrinking)	0.00%	0.00%	Compare
NKTR Nektar Therapeutics	$1.3B	— (loss-making)	— (loss-making)	−9.34% (below 0%: shrinking)	n/m	−65.73% (below 0%: shrinking)	100.00%	(417.94%)	Compare
DRTS Alpha Tau Medical Ltd.	$1.2B	— (loss-making)	—	—	n/m	−30.42% (below 0%: shrinking)	0.00%	0.00%
SNDX Syndax Pharmaceuticals, Inc.	$1.2B	— (loss-making)	— (loss-making)	+91.76% (above 0%: growing)	n/m	+65.47% (above 0%: growing)	95.59%	(54.95%)	Compare
TSHA Taysha Gene Therapies, Inc.	$1.2B	— (loss-making)	— (loss-making)	+206.77% (above 0%: growing)	n/m	−100.28% (below 0%: shrinking)	100.00%	0.00%	Compare
LBRX LB Pharmaceuticals Inc	$1.2B	— (loss-making)	—	—	n/m	−579.03% (below 0%: shrinking)	—	0.00%	Compare
BCAX Bicara Therapeutics Inc.	$1.2B	— (loss-making)	—	—	n/m	−72.95% (below 0%: shrinking)	—	0.00%	Compare
DMRA Galecto, Inc.	$1.2B	— (loss-making)	—	—	n/m	−877.51% (below 0%: shrinking)	0.00%	0.00%	Compare
VOR Vor Biopharma Inc.	$1.1B	— (loss-making)	—	—	n/m	−47.59% (below 0%: shrinking)	0.00%	—	Compare
Median of peers	$1.2B	—	—	+91.76%	—	−69.79%	47.80%	0.00%

All 614 Biotechnology stocks →

Alpha Tau Medical Ltd. (DRTS) key facts

Alpha Tau Medical Ltd. (DRTS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, DRTS traded at $12.29, a market capitalization of $1.2 billion.
Return on equity was −61.0% and debt-to-equity 0.15.

Source: company filings (standardised) and stockrow calculations.